✦ LIBER ✦

A triumph for physiology driving drug discovery: the potential impact of dipeptidyl peptidase-IV inhibitors in type 2 diabetes

✍ Scribed by Richard Donnelly

Book ID: 109044482
Publisher: John Wiley and Sons
Year: 2007
Tongue: English
Weight: 61 KB
Volume: 9
Category: Article
ISSN: 1462-8902
DOI: 10.1111/j.1463-1326.2007.00706.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

ChemInform Abstract: Discovery of Carmeg

ChemInform Abstract: Discovery of Carmegliptin (I): A Potent and Long-Acting Dipeptidyl Peptidase IV Inhibitor for the Treatment of Type 2 Diabetes.

✍ Patrizio Mattei; et al. et al. 📂 Article 📅 2010 🏛 John Wiley and Sons ⚖ 16 KB 👁 2 views

ChemInform Abstract: The Asymmetric Synt

ChemInform Abstract: The Asymmetric Synthesis of Sitagliptin, a Selective Dipeptidyl Peptidase IV Inhibitor for the Treatment of Type 2 Diabetes.

✍ Feng Liu; Wansheng Yu; Wenhua Ou; Xiaoke Wang; Libo Ruan; Yiming Li; Xijiang Pen 📂 Article 📅 2010 🏛 John Wiley and Sons ⚖ 23 KB 👁 1 views

## Abstract Key step in the improved synthetic pathway to sitagliptin (VII), a new DPP‐IV inhibitor for the treatment of type 2 diabetes mellitus, is an asymmetric Michael addition to give intermediate (IV).

ChemInform Abstract: Discovery of DA-122

ChemInform Abstract: Discovery of DA-1229 (I): A Potent, Long Acting Dipeptidyl Peptidase-4 Inhibitor for the Treatment of Type 2 Diabetes.

✍ Bong Jin Lee; et al. et al. 📂 Article 📅 2011 🏛 John Wiley and Sons ⚖ 20 KB 👁 1 views

(3R)-4-[(3R)-3-Amino-4-(2,4,5-trifluorop

(3R)-4-[(3R)-3-Amino-4-(2,4,5-trifluorophenyl)butanoyl] -3-(2,2,2-trifluoroethyl)-1,4-diazepan-2-one, a Selective Dipeptidyl Peptidase IV Inhibitor for the Treatment of Type 2 Diabetes.

✍ Tesfaye Biftu; et al. et al. 📂 Article 📅 2007 🏛 John Wiley and Sons ⚖ 13 KB 👁 1 views